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Abstract
Cystic fibrosis (CF) is a lethal monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene that entails the (diagnostic) increase in sweat electrolyte concentrations, progressive lung disease
with chronic inflammation and recurrent bacterial infections, pancreatic insufficiency, and male infertility. Therapies
aimed at restoring the CFTR defect have emerged. Thus, a small molecule which facilitates chloride channel opening,
the potentiator Ivacaftor, has been approved for the treatment of CF patients bearing a particular class of rare CFTR
mutations. However, small molecules that directly target the most common misfolded CFTR mutant, F508del, and
improve its intracellular trafficking in vitro, have been less effective than expected when tested in CF patients, even in
combination with Ivacaftor. Thus, new strategies are required to circumvent the F508del-CFTR defect. Airway and
intestinal epithelial cells from CF patients bearing the F508del-CFTR mutation exhibit an impressive derangement of
cellular proteostasis, with oxidative stress, overactivation of the tissue transglutaminase (TG2), and disabled autophagy.
Proteostasis regulators such as cysteamine can rescue and stabilize a functional F508del-CFTR protein through
suppressing TG2 activation and restoring autophagy in vivo in F508del-CFTR homozygous mice, in vitro in CF patient-
derived cell lines, ex vivo in freshly collected primary patient’s nasal cells, as well as in a pilot clinical trial involving
homozygous F508del-CFTR patients. Here, we discuss how the therapeutic normalization of defective proteostasis can
be harnessed for the treatment of CF patients with the F508del-CFTR mutation.
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Cystic fibrosis (CF), the most common lethal monogenic
disease in Caucasians, is caused by mutations in the
gene coding for cystic fibrosis transmembrane conduct-
ance regulator (CFTR), a 1480-amino acid protein func-
tioning as a chloride channel at the apical membrane
from the epithelial cells [1]. CF is a systemic disease,
although the extent of clinical manifestations is highly
heterogeneous in distinct organs [1–3]. The phenotypic
consequences of the defective CFTR function comprise
insufficiency of the exocrine pancreas, increased electro-
lytes in sweat, male infertility due to congenital absence
of the vas deferens, and—most prevalent—a debilitating
progressive lung disease resulting from decreased
mucociliary clearance with accumulation of thick, sticky
mucus, chronic inflammation, and persistent and un-
treatable bacterial colonization causing frequent chest
infections, mainly by Pseudomonas aeruginosa [1–3].
Exocrine pancreatic insufficiency frequently occurs in
patients with CF. It is mainly associated with “severe”
CFTR mutations, where both alleles are affected by
complete or major loss of function. Other gastrointes-
tinal complications comprise recurrent abdominal pain
or acute recurrent pancreatitis. Moreover, thickened se-
cretions blocked in the bile ducts may cause progressive
liver damage. Salty-tasting skin, poor growth, and poor
weight gain despite normal food intake often appear in
infancy, as bowel obstruction due to meconium ileus
may occur in neonates. The causes of growth failure are
multifactorial and include chronic lung infection, poor
digestibility and absorption of nutrients through the
gastrointestinal tract, and increased metabolic demand
due to chronic illness.
* Correspondence: raia@unina.it; kroemer@orange.fr; luigi.maiuri@gmail.com
2Regional Cystic Fibrosis Center, Pediatric Unit, Department of Translational
Medical Sciences, Federico II University, Naples 80131, Italy
3Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des
Cordeliers, Paris, France
1European Institute for Research in Cystic Fibrosis, Division of Genetics and
Cell Biology, San Raffaele Scientific Institute, Milan 20132, Italy
Full list of author information is available at the end of the article
© 2016 Esposito et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Esposito et al. Molecular and Cellular Pediatrics  (2016) 3:13 
DOI 10.1186/s40348-016-0040-z
Diagnostic procedures in CF include routine newborn
screening (when blood concentrations of trypsinogen are
usually measured as a surrogate marker), sweat testing,
and genetic analysis. Infants with an abnormal finding in
newborn screen need the sweat test to confirm the CF
diagnosis. In countries in which newborn screening is
not available, most individuals are primarily diagnosed
by means of the sweat test, in which pilocarpine is
applied to the skin to stimulate local sweating followed
by iontophoresis to determine the concentration of
chloride. CF can also be diagnosed by the identification
of mutations in the CFTR gene.
Despite increased survival to date, several treatment
methods of CF are purely symptomatic and hence fail to
address the primary cause of CF, namely the loss of
function of CFTR. New anti-inflammatory and antibiotic
drugs are on the agenda of drug discovery approaches
and clinical trials in CF patients [4].
Approximately 2000 mutations, most of which are dis-
ease relevant, have been identified in the CFTR gene
and then categorized in six different classes according to
their functional impact [5]. They include severe CFTR
mutations that result in negligible protein synthesis
(class I), misfolded mutants with defective intracellular
trafficking (class II), or mutated proteins that are ortho-
topically expressed but exhibit impaired channel func-
tion (class III). Mutation-specific approaches aimed at
correcting the CFTR defect (CFTR-repairing therapies)
have recently emerged [5, 6]. These strategies are com-
monly focused on the identification of molecules that
directly target mutant CFTR. These compounds are
either capable of correcting the trafficking of CFTR
mutants (“correctors”: agents that ensure the expression
of the mutated protein at the apical plasma membrane)
or improving channel function (“potentiators”: agents
that reinstate the channel function of mutated CFTR
proteins that are orthotopically expressed).
An orally available compound identified by high-
throughput screening, the CFTR potentiator VX-770
(Ivacaftor, trade name Kalydeco), has been shown to effi-
ciently reduce chloride levels in sweat and to improve
lung function in CF patients harboring the G551D CFTR
genotype, a rare class III CFTR mutant that affects only
4–5 % of CF patients [7, 8]. However, no effective treat-
ments are available for the most common class II CFTR
mutations. Indeed, one single mutation, p.phe508-
delCFTR, commonly known as F508del-CFTR (catego-
rized in class II), accounts for about 70 % of CFTR
chromosomes worldwide and is present in approxi-
mately 90 % of CF patients [5, 6]. F508del-CFTR is a
misfolded protein mostly retained at the endoplasmic
reticulum where it is immediately sent for degradation
[9]. Despite the gating defect linked to the impaired pro-
tein conformation, F508del-CFTR shows some degree of
function if rescued and stabilized at the plasma mem-
brane (PM) [3–5]. Restoring about 20–30 % of CFTR
function is believed to confer an at least partial clinical
benefit to CF patients. However, although F508del-
CFTR can be rescued at the PM by CFTR correctors in
vitro [9], this mutant CFTR protein is unstable at the
cell surface and rapidly redirected from endosomal re-
cycling towards lysosomal delivery and degradation. The
investigational F508del corrector VX-809 (Lumacaftor),
which is endowed with rescuing efficacy in vitro and in
primary cultures of lung cells from F508del-CFTR
homozygous CF patients [9], showed only the modest ef-
ficacy in a phase II clinical trial in CF patients homozy-
gous for the F508del-CFTR mutant [10]. Moreover, only
marginal effects on lung function have been observed in
phase II, and phase III randomized clinical trials aimed
at testing the efficacy of a combination of the corrector
Lumacaftor and the potentiator Ivacaftor [11–14]. Not-
ably, no effects of treatment on sweat chloride, a surro-
gate marker of CFTR function in vivo, have been
reported [12]. New combinations of correctors and
potentiators are being evaluated in clinical trials in CF
patients bearing F508del-CFTR mutation. However, the
preclinical evidence supporting the putative effectiveness
of chronic administration of the potentiator VX-770
together with a CFTR corrector (either VX-809 or VX-
661) is lacking, and the mechanisms of action of these
investigational correctors are still poorly understood.
This suggests that interventions other than simple cor-
rection or potentiation of mutated CFTR are required in
CF therapy.
Proteostasis network is deranged in CF epithelia
Recently, more general therapeutic strategies aiming at
the improvement of proteostasis have emerged [15–18].
These strategies have been designed to improve the cel-
lular environment perturbed by the lack of a functional
CFTR instead of directly targeting the mutant CFTR
protein. Such a novel approach is based on recent evi-
dence indicating that CFTR does not act as a pure ion
channel but is a platform for cellular signaling within a
proper cellular environment. Given the heterogeneity of
signaling pathways, this new vision of CFTR implies that
its function is conditioned by its cellular environment.
Importantly, the protein interactomes of wild-type (WT)
CFTR and the most frequent CFTR mutant, F508del-
CFTR, are rather different [17, 18]. There is growing
consensus that indirect measures to correct the deficient
proteostasis of CFTR may be fruitful. Proteostasis modu-
lators may reestablish the plasma membrane localization
and function of F508del-CFTR by remodeling the
F508del-CFTR interactome, for instance by avoiding
unwanted interactions and reinstating desirable protein-
protein interactions for F508del-CFTR [17]. Notably,
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CFTR is a key player of proteostasis in the epithelial
cells, as the inhibition of CFTR function derails the
intracellular environment and ignites the disposal of
CFTR itself in a feed-forward loop [19].
A complex derangement of proteostasis takes place in
human bronchial F508del-CFTR homozygous epithelial
cell lines as well as in the lungs from F508del-CFTR
homozygous (CftrF508del) mice [20–23]. Dysfunctional
F508del-CFTR protein induces a complex alteration of the
post-translational network with increased generation of
reactive oxygen species (ROS) that lead to SUMOylation
with decreased ubiquitylation and persistent activation of
pro-fibrotic tissue transglutaminase 2 (TG2) [20, 21]. TG2
is a versatile multifunctional protein that changes its func-
tion depending on external and internal signals [24–26].
In the presence of high Ca2+ levels, TG2 can act as a
crosslinking enzyme, catalyzing several post-translational
modifications of target proteins. At low Ca2+ concentra-
tions, TG2 may function as a G-protein or as a protein
disulfide isomerase, thus contributing to the functionality
of mitochondrial respiratory chain complexes [24–26].
Increased levels of TG2 are observed in several human
pathologies including neurodegenerative diseases such as
Alzheimer’s, Huntington’s, and Parkinson’s diseases, as
well as in chronic inflammatory conditions [24–26].
Defective CFTR inhibits autophagy
TG2 overactivation in the CF epithelial cells leads to func-
tional sequestration of Beclin 1 (BECN1) [22], a protein
essential for autophagy, a mechanism required for cell sur-
vival, and involved in the pathogenesis of several human
diseases [27–30]. Autophagy is pivotal in promoting cellu-
lar clearance of protein aggregates and removal of ROS
sources, such as damaged mitochondria and results in the
lysosomal degradation of cytoplasmic organelles or cyto-
solic components after their sequestration in two-
membraned vesicles (autophagosomes) [27–30]. BECN1 is
a haploinsufficient tumor suppressor protein essential for
autophagosome formation. BECN1 dissociates from Bcl-2
during stress conditions, such as starvation, thus promot-
ing autophagy. Subsequently, BECN1 interacts with the
class III phosphatidyl-inositol 3 kinase (PI3K), human
vacuolar protein sorting (hVps)34, facilitating its activa-
tion. The ER-associated class III PI3K activity is crucial for
the initiation of autophagosome formation [27–30].
We discovered that human and mouse CF airways
exhibit a defect in autophagy, as indicated by reduced
autophagosome formation, and the accumulation of
sequestrosome 1 (SQSTM1) [22], a major autophagic
substrate also known as p62 [31]. This occurs in spite of
the normal expression of major autophagy genes [22]. A
defective autophagic response to bacterial infection has
also been reported in murine CF macrophages in which
reduced autophagosome formation promotes the survival
of Burkholderia cenocepacia, as well as the pro-
inflammatory hypersecretion of IL-1β [32, 33].
Restoration of autophagy circumvents F508del-CFTR
defect
Genetic depletion of SQSTM1, transgene-enforced BECN1
overexpression, or addition of autophagy-stimulatory pro-
teostasis regulators, such as cystamine (or its reduced form
cysteamine), can increase the expression level of F508del-
CFTR protein and restore its function at the PM, either in
CFTR homozygous CFBE41o- bronchial epithelial cell lines
or in primary nasal epithelial cells freshly collected from
CF patients bearing F508del-CFTR mutation, as well as in
the lungs from CftrF508del mice [34, 35]. As a consequence,
restoration of autophagy reduces lung inflammation in
CftrF508del mice. Notably, cysteamine has a long-lived ac-
tion because this drug is able to allow F508del-CFTR to
reside at the PM after rescue for 24 h beyond its washout
[34, 35]. These long-term effects of cysteamine are abro-
gated if CFTR function is simultaneously inhibited, or
CFTR is depleted during washout [34, 35]. Importantly,
the effects of cysteamine in reducing lung inflammation
extend up to several days in vivo in CftrF508del mice, unless
autophagy is inhibited by 3-methyl-adenine (3-MA) after
cysteamine withdrawal [34, 35]. This suggests that the res-
toration of a proper autophagy flux can interrupt the
CFTR-driven vicious cycle that derails the proteostasis net-
work as, once stabilized at the epithelial surface, F508del-
CFTR can sustain its own PM residence and function.
Proteostasis regulators prevent intestinal
manifestations in CF mice
In pigs and mice, the loss of the function mutations of
Cftr causes a predominantly intestinal phenotype. Thus,
50 to 90 % of cftr KO and up to 40 % of CftrF508del mice
die within the first 4 weeks after birth, mostly due to in-
testinal obstruction, unless they are kept under a special
diet that reduces the risk of obstruction [35]. We ob-
served that oral treatment for 5 weeks with cysteamine
significantly reduced mortality, improved weight gain,
and increased the expression of functional CFTR protein
at the intestinal level, at the same time, that it restored
BECN1 protein expression to wild-type levels. Such a
treatment is also capable of reducing lung inflammation
[35].
Proteostasis regulators increase F508del-CFTR
stability
Ensuring stability to the rescued F508del-CFTR mutant
is a major concern in CFTR repairing therapies, as this
mutant is rapidly dismissed from the PM after rescue
and directed towards lysosomal degradation. Recent
strategies aim at overcoming this issue through a com-
bination of corrector and potentiator molecules, the
Esposito et al. Molecular and Cellular Pediatrics  (2016) 3:13 Page 3 of 5
latter aimed at enhancing channel activity after rescue.
However, Cholon et al. and Veit et al., showed that the
chronic administration of potentiators, such as Ivacaftor,
is detrimental to F508del-CFTR stability, as it instead
favors PM disposal of the mutant protein [36, 37].
Indeed, the mechanisms responsible for the premature
F508del-CFTR removal from the PM after rescue are
not fully understood. The rescued F508del-CFTR under-
goes CHIP-mediated PM ubiquitination [38] and then is
targeted by the ubiquitin-binding protein SQSTM1/p62,
which accumulates at the PM as the consequence of dis-
abled autophagy [34, 35]. The resulting complex com-
posed by F508del-CFTR and SQSTM1/p62 is directed to
the lysosomes for degradation [34, 35]. Moreover, defect-
ive PI3K complex III activity, due to functional sequestra-
tion of BECN1, impairs CFTR recycling, thus enhancing
CFTR disposal.
Besides these autophagy-dependent mechanisms, other
perturbations of the proteostasis network can influence
F508del-CFTR stability at the PM. Peptide fragments
released from proteolytically cleaved F508del-CFTR pro-
voke an overactivation of a pleiotropic protein kinase
(CK2), which in turn contributes to the fragmentation
and poor stability of F508del-CFTR [39, 40]. The inhib-
ition of overactive CK2 by specific inhibitors, such as
CX-4945, or by means of natural compounds with
known safety profile, as the over-the-counter flavonoid
epigallocatechin gallate (EGCG), contributes to confer
PM stability to F508del-CFTR mutant, thus prolonging
the persistence of the mutant F508del-CFTR protein at
the epithelial surface after rescue by cysteamine [35].
Proteostasis regulators can restore F508del-CFTR
function in CF patients
Prompted by these pre-clinical results, we recently
launched clinical pilot trials to evaluate the combin-
ation of cysteamine, already approved for patients
with cystinosis (FDA number NDA020392) [41], and
EGCG for the treatment of F508del-CFTR homozy-
gous patients [30]. In this phase 2 trial, cysteamine
plus EGCG restored autophagy and improved CFTR
function while rescuing the expression of mature
(band C) CFTR protein from the nasal epithelial cells
in vivo. Notably, the functional rescue of F508del-
CFTR is coupled to, and correlated with, a decrease
of chloride concentrations in sweat, as well as a re-
duction of the abundance of inflammatory cytokines
in the sputum [35]. These findings indicate that such
a combination treatment acts “on target”. They also
indicate that it is feasible to correct the F508del-
CFTR defect by manipulating the proteostasis net-
work, thus rescuing the mutant CFTR protein and
then normalizing its PM stability.
Conclusions
We believe that any CF treatment should aim at rescu-
ing the expression and function of functional CFTR and
hence target the true causes of the disease rather than
its signs. Manipulation of proteostasis network offers
new perspectives for the design of candidate drugs
aimed at repairing the primary CFTR defect, well
beyond the idea that such molecules must directly inter-
act with mutant CFTR protein. The proteostasis network
is unique to each cell type and tissues. Thus, finding
appropriate proteostasis regulators implies a profound
understanding of the pathogenic mechanisms operating
within each peculiar cellular context. Based on our
experience, we recommend a translational research
approach that comprises studies on appropriate animal
models and freshly collected primary cells from CF
patients to develop a strong pre-clinical rationale before
evaluating drugs in the clinic. Finally, we speculate that
proteostasis modulators might represent an attractive
approach to other human conformational diseases,
including some neurodegenerative disorders, beyond CF.
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